专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

AU2003209544A8 Use of mycobacterium w in the treatment of asthama(obstructive lung disease) 未知
公开(公告)号：AU2003209544A8
公开(公告)日：2003-09-22
申请号：AU2003209544
申请日：2003-03-11
申请人： KHAMAR BAKULESH MAFATLAL , MODI RAJIV INDRAVADAN
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K35/74 , A61K39/00 , A61K39/04 , A61P11/06

12. 发明专利

AU2003209534A8 The method of treating tuberculosis 未知
公开(公告)号：AU2003209534A8
公开(公告)日：2003-09-22
申请号：AU2003209534
申请日：2003-03-04
申请人： KHAMAR BAKULESH MAFATLAL , MODI RAJIV INDRAVADAN
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K35/74 , A61P31/06 , C12R1/32
摘要： The invention relates to the method of treating tuberculosis comprises use of a microorganism Mycobacterium w for the treatment of tuberculosis.

13. 发明专利

AU2002348738A1 THE METHOD OF TREATING CANCER 未知
公开(公告)号：AU2002348738A1
公开(公告)日：2003-06-23
申请号：AU2002348738
申请日：2002-12-10
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K47/04 , A61K35/74 , A61K39/04 , A61K39/39 , A61K47/06 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/42 , A61P35/00 , A61P35/04
摘要： Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from ‘Mycobacterium w’ (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobacterium w containing formulations is associated with decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves tolerance to other therapies.

14. 发明专利

CA2472481A1 USE OF MYCOBACTERIUM W FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE INFECTION 未知
公开(公告)号：CA2472481A1
公开(公告)日：2002-07-25
申请号：CA2472481
申请日：2002-01-17
申请人： KHAMAR BAKULESH MAFATLAL , MODI INDRAVADAN AMBALAL
发明人： KHAMAR BAKULESH MAFATLAL , MODI INDRAVADAN AMBALAL
IPC分类号： A61K39/00 , A61K39/04 , A61P31/18 , A61K39/39
摘要： Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides method of using mycobacterium w for the management of HIV. According to present invention mycobacterium w when given intradermally is effective in prophylaxis and treatment of AIDS or AIDS related complex (ARC). It is found to improve immunity as well as CD4 count. It is found to eliminate symptoms like fever, diarrhea. The effect is seen even when no antiretrovirals are used.

15. 发明专利

AU6415698A The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients 未知
公开(公告)号：AU6415698A
公开(公告)日：1999-10-18
申请号：AU6415698
申请日：1998-04-03
申请人： CADILA PHARM LTD , MODI RAJIV INDRAVADAN , BANSAL YATISH KUMAR , KHAMAR BAKULESH MAFATLAL
发明人： MODI RAJIV INDRAVADAN , BANSAL YATISH KUMAR , KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K45/00 , A61K9/24 , A61K9/48 , A61K9/50 , A61K35/74 , A61P1/00 , A61P31/00
摘要： Micro organisms are useful in management of diseases including diarrhoea and gastro intestinal diseases like pseudomembranous colitis, megacolon etc. They are also useful in prevention of gastro intestinal disturbances and diseases caused by anti-infective agents like ampicillin, amoxycillin, cloxacillin, clauvanic acid, cefuroxime axetel, cephalixin, erythromycin etc. For prevention micro organisms are to be taken along with anti infective agents. When micro organisms are combined with anti-infective agents for ease of administration and improving compliance and therapeutic effect, the combination is not found to be stable at room temperature as micro organisms are sensitive to anti-infective agents and are destroyed by effect of anti-infective agent in composition. The present invention relates to the process of preparing a stable fixed dose composition of anti-infective agent with micro organism as active ingredient. The process includes preparation of various dosage forms for oral route like capsule, tablet and liquid formulation. The process comprises of providing an appropriate barrier by way of selected coating procedure to one of the active ingredients in such a way that micro organisms are not affected by anti-infective agents. This results in a stable composition. By using an appropriate coating technique composition is made to remain stable over a period of 3-36 months at ambient/room temperature. The ratio of micro organism to anti-infective agents in a composition can be 1:2 to 1:25 by weight. The ratio of 1:5 by weight is found to be optimal for the purpose. The amount of coating is dependent on the type of coating technique, dosage form i.e. capsule, tablet or liquid and desired self life. The micro organisms of the composition were found to be active after variable time period. They also provided therapeutic effect and eliminated gastro intestinal disturbances associated with anti-infective agents when evaluated in humans.

16. 发明专利

CA2632353C VACCINE ADJUVANTS COMPRISING MYCOBATERIUM 未知
公开(公告)号：CA2632353C
公开(公告)日：2018-02-20
申请号：CA2632353
申请日：2006-04-21
申请人： KHAMAR BAKULESH MAFATLAL , MODI INDRAVADAN AMBALAL , MODI RAJIV INDRAVADAN , GHOSH PRASANTA KUMAR , DESAI NIRAV
发明人： KHAMAR BAKULESH MAFATLAL , MODI INDRAVADAN AMBALAL , MODI RAJIV INDRAVADAN , GHOSH PRASANTA KUMAR , DESAI NIRAV
IPC分类号： C12N1/20 , A61K39/00
摘要： The invention relates. to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition, e.g. immune naÊve or preimmunised status.

17. 发明专利

CA2469266C THE METHOD OF TREATING CANCER 未知
公开(公告)号：CA2469266C
公开(公告)日：2014-02-11
申请号：CA2469266
申请日：2002-12-10
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K35/66 , A61K47/04 , A61K35/74 , A61K39/04 , A61K39/39 , A61K47/06 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/42 , A61P35/00 , A61P35/04
摘要： Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from "Mycobacterium w' (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobacterium w containing formulations is associated with decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves tolerance to other therapies.

18. 发明专利

AU2006238906B2 Vaccine adjuvants 未知
公开(公告)号：AU2006238906B2
公开(公告)日：2013-04-11
申请号：AU2006238906
申请日：2006-04-21
申请人： DESAI NIRAV , GHOSH PRASANTA KUMAR , KHAMAR BAKULESH MAFATLAL , MODI INDRAVADN AMBALAL , MODI RAJIV INDRAVADAN
发明人： KHAMAR BAKULESH MAFATLAL , GHOSH PRASANTA KUMAR , MODI INDRAVADN AMBALAL , MODI RAJIV INDRAVADAN , DESAI NIRAV
IPC分类号： C12N1/20 , A61K39/00
摘要： The invention relates. to a novel adjuvant

19. 发明专利

AU2002225263B2 Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection 未知
公开(公告)号：AU2002225263B2
公开(公告)日：2005-10-27
申请号：AU2002225263
申请日：2002-01-17
申请人： KHAMAR BAKULESH MAFATLAL , MODI INDRAVADAN AMBALAL
发明人： MODI INDRAVADAN AMBALAL , KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K39/00 , A61K39/04 , A61P31/18 , A61K039/04 , A61K039/39 , A61P031/18
摘要： Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides method of using mycobacterium w for the management of HIV. According to present invention mycobacterium w when given intradermally is effective in prophylaxis and treatment of AIDS or AIDS related complex (ARC). It is found to improve immunity as well as CD4 count. It is found to eliminate symptoms like fever, diarrhea. The effect is seen even when no antiretrovirals are used.

20. 发明专利

EA005672B1 ХЕМОСЕНСИБИЛИЗАТОР 未知
公开(公告)号：EA005672B1
公开(公告)日：2005-04-28
申请号：EA200200288
申请日：2001-06-26
申请人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K31/00 , A61K31/4525 , A61K31/445 , C07D211/16
摘要： Хемотерапевтическиеагентыиспользуютсядлялеченияинфекций, вызванныхбактериями, вирусами, простейшими, паразитами, иразличныхзлокачественныхзаболеваний, такихкакрак. Главнойпроблемой, связаннойс использованиемхемотерапевтическихагентов, являетсяустойчивостьк хемотерапевтическимагентам. Механизмы, лежащиев основеустойчивостипоотношениюк хемотерапевтическимагентам, включаютв себядезактивацию/модификациюантибиотика (бета-лактамы, хлорамфеникол), нечувствительныйцелевойсайт (бета-лактамы, гликопептиды, макролиды, тетрациклины), сниженнуюаккумуляциюмедикаментав видеусиленногооттока (тетрациклины, хлорохин, макролиды, противораковыемедикаменты), обходшагачувствительностиантибиотика (метициллин, сульфонамиды) ит.д. Общиемеханизмы, лежащиев основеустойчивостик медикаментам, заключаютсяв ограниченииконцентрациимедикаментав местедействия, обычновнутриклетки. Этоможетпроисходитьв видеограничениявхождениямедикаментав клеткузасчётразличныхмеханизмов, втомчислеизменяющегосяпропусканияклеточнойстенки. Такжеэтоможетпроисходитьв видеудалениямедикаментаизместадействия, например, внутриклеточного, такчтонедостигаетсятерапевтическаяконцентрация. Медикаменты, восстанавливающиечувствительностьк хемотерапевтическимагентам, широкоизвестныкакхемосенсибилизаторы. Былообнаружено, чтосоединения, принадлежащиек группе R-1-3-бензодиаксола, являютсяхемосенсибилизаторамипонастоящемуизобретению. Пиперинявляетсяоднимизтакихсоединений, принадлежащихк группе R-1-3-бензодиаксола, ипонастоящемуизобретениюявляетсяхемосенсибилизатором. Пиперин

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式